Waheed Abdul, Klosterman Emily, Lee Joseph, Mishra Ankita, Narasimha Vijay, Tuma Faiz, Bokhari Faran, Haq Furqan, Misra Subhasis
Surgery, Brandon Regional Hospital, Brandon, USA.
General Surgery, East Tennessee State University, Johnson City, USA.
Cureus. 2019 Sep 16;11(9):e5670. doi: 10.7759/cureus.5670.
Introduction The long-term patency of the grafts used during the coronary artery bypass grafting (CABG) is one of the most significant predictors of the clinical outcomes. The gold standard graft used during CABG with the best long-term patency rate and the better clinical outcomes is left internal thoracic artery (LITA) grafted to the left coronary artery (LCA). The controversy lies in choosing the second-best conduit for the non-left coronary artery (NLCA) with similar patency rate as LITA. This meta-analysis examines the long-term patency and clinical outcomes of all arterial grafts versus all venous grafts used during the CABG. Methods A comprehensive literature search of all published randomized control trials (RCTs) assessing long-term patency and clinical outcomes of grafts used in CABG was conducted using PubMed, Cochrane Central Registry of Controlled Trials, and Google Scholar (1966-2018). Keywords searched included combinations of "CABG", "venous grafts in CABG", "arterial grafts in CABG", "radial artery grafts in CABG", "gastroepiploic artery grafts in CABG", "patency and clinical outcomes". Inclusion criteria included: RCTs comparing the long-term patency, and clinical outcomes of radial artery, right internal thoracic artery, gastroduodenal artery, and saphenous vein grafts used in CABG. Long-term patency of the grafts and clinical outcomes were analyzed. Results Eight RCTs involving 2,091 patients with 1,164 patients receiving arterial grafts and 927 patients receiving venous grafts were included. There was no difference between the long-term patency rate (relative risk (RR) = 1.050, 95% confidence interval (CI) = 0.949 to 1.162, and p = 0.344), overall mortality rate (RR = 1.095, 95% CI = 0.561 to 2.136, and p = 0.790), rate of myocardial infarction (MI) (RR = 0.860, 95% CI = 0.409 to 1.812, and P = 0.692), and re-intervention rate (RR = 0.0768, 95% CI = 0.419 to 1.406, and P = 0.392) between arterial and venous grafts. Conclusion The use of arterial conduits over the venous conduits has no significant superiority regarding the long-term graft patency, the rate of MI, overall mortality, and the rate of revascularization following CABG. Additional adequately powered studies are needed to further evaluate the long-term outcomes of arterial and venous grafts following the CABG.
引言 冠状动脉旁路移植术(CABG)中使用的移植物的长期通畅性是临床结果的最重要预测指标之一。CABG中使用的具有最佳长期通畅率和更好临床结果的金标准移植物是左胸廓内动脉(LITA)移植到左冠状动脉(LCA)。争议在于为非左冠状动脉(NLCA)选择与LITA通畅率相似的第二最佳管道。这项荟萃分析研究了CABG中使用的所有动脉移植物与所有静脉移植物的长期通畅性和临床结果。
方法 使用PubMed、Cochrane对照试验中央注册库和谷歌学术搜索(1966 - 2018年)对所有已发表的评估CABG中使用的移植物长期通畅性和临床结果的随机对照试验(RCT)进行全面文献检索。检索的关键词包括“CABG”、“CABG中的静脉移植物”、“CABG中的动脉移植物”、“CABG中的桡动脉移植物”、“CABG中的胃网膜动脉移植物”、“通畅性和临床结果”的组合。纳入标准包括:比较CABG中使用的桡动脉、右胸廓内动脉、胃十二指肠动脉和大隐静脉移植物的长期通畅性和临床结果的RCT。分析移植物的长期通畅性和临床结果。
结果 纳入了8项RCT,涉及2091例患者,其中1164例接受动脉移植物,927例接受静脉移植物。动脉移植物和静脉移植物在长期通畅率(相对风险(RR)= 1.050,95%置信区间(CI)= 0.949至1.162,p = 0.344)、总死亡率(RR = 1.095,95% CI = 0.561至2.136,p = 0.790)、心肌梗死(MI)发生率(RR = 0.860,95% CI = 0.409至1.812,P = 0.692)和再次干预率(RR = 0.0768,95% CI = 0.419至1.406,P = 0.392)方面没有差异。
结论 在CABG后,使用动脉管道而非静脉管道在移植物长期通畅性、MI发生率、总死亡率和血运重建率方面没有显著优势。需要更多有足够样本量的研究来进一步评估CABG后动脉和静脉移植物的长期结果。